Emodan Dosage/Direction for Use

Management of Nausea and Vomiting Induced by Cytotoxic Chemotherapy and Radiography: Adults: The emetogenic potential of cancer treatment varies according to the doses and combination of chemotherapy and radiotherapy regimens used. The route of administration is oral, intravenous and intramuscular. Dose of Ondansetron should be flexible in the range of 8-32 mg as Ondansetron a day and selected as shown as follows.
In less emetogenic chemotherapy and radiotherapy: Ondansetron 8 mg should be administered as a slow intravenous Injection or intramuscular injection immediately before treatment or orally 1 to 2 hours before treatment, followed by 8 mg orally after 12 hours.
To protect against delayed emesis, Ondansetron should be continued orally, 8 mg bid for up to 5 days after a course of treatment.
In highly emetogenic chemotherapy (e.g. regimens containing cisplatin): A dose of 8 mg by slow intravenous injection or intramuscular injection immediately before chemotherapy, followed by two further intravenous doses of 8 mg 2-4 hours apart, prn by a constant infusion of 1 mg/hour for up to 24 hours.
Alternatively, a single dose of 32 mg diluted in 50-100 mL of saline or other compatible infusion fluid and infused over 15 minutes immediately before chemotherapy.
The efficacy of Ondansetron in highly emetogenic chemotherapy may be enhanced by slow intravenous injection of dexamethasone sodium phosphate, 20 mg administered prior to chemotherapy.
To protect against delayed emesis, Ondansetron should be continued orally, 8 mg bid for up to 5 days after a course of treatment.
Children: Ondansetron may be administered as a single intravenous dose of 5 mg/m² over 15 minutes immediately before chemotherapy, followed by four mg orally every 12 hours or twice daily should be continued for up to 5 days after a course of treatment.
Prevention and Treatment of Post-Operative Nausea and Vomiting: Adults: For the prevention of post-operative nausea and vomiting: Ondansetron may be administered orally at a dose of 16 mg given 1 hour prior to anaesthesia.
Ondansetron may be administered orally at a dose of 8 mg given 1 hour prior to anaesthesia, followed by two further doses of 8 mg at 8 hourly intervals.
Alternatively, a single dose of 4 mg may be given by slow intravenous injection at induction of anaesthesia.
For the treatment of established post-operative nausea and vomiting: A single dose of 4 mg given by slow intravenous injection is recommended.
Children: For the prevention and treatment of post-operative nausea and vomiting.
Ondansetron may be slowly administered as a single intravenous dose of 0.1 mg/kg up to 4 mg, before, during or after anesthesia.
Patients With Renal Impairment: No alternation of daily dosage or frequency of dosing, or route of administration is required.
Patients with Hepatic Impairment: Clearance of Ondansetron is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients, a total daily dose of 8 mg should not be exceeded.
Patients with poor Sparteine/Debrisoquine metabolism: Patients with metabolism disorder of Sparteine/Debrisoquine, elimination half-life of Ondansetron have not changed. No specific studies have been conducted in patients with metabolism disorder of Sparteine/Debrisoquine. No change for dosage and administration.
Or as prescribed by the physician.